Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

Latest Pancreatic Hormone Articles

Pancreatic Hormone Archives
Print | Email | Share | Comments (0)

FDA OKs Sale of Combo Drug JANUMET® XR


Feb 6, 2012

The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC.

Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that reduces the production of glucagon, a pancreatic hormone that increases blood glucose levels. Metformin, an established and widely used drug for treating type 2, works by decreasing the liver's production of glucose.

Merck's randomized, double-blind, placebo-controlled study of JAMUMET XR in 1,091 type 2 patients showed that over a 24-week period, the sitagliptin-metformin combination helped patients achieve a 2.1% reduction in A1C levels, down from a mean baseline of 8.8%.

JANUMET XR's once-daily regimen makes it easier for type 2 patients to follow their therapy routine. Dosage of the drug may vary according to whether patients are taking other drugs, such as insulin or sulfonylureas. JANUMET XR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

 


Categories: Blood Glucose Levels, Diabetes, Diabetes, Diabetic Ketoacidosis, DPP-4 Inhibitor, Extended-Release Metformin, Glucagon, Janumet, JANUMET XR, Januvia, Juvisync, Merck, Metformin, Pancreatic Hormone, Sitagliptin, Type 1 Issues, Type 2 Diabetes, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Feb 6, 2012

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.